The Food and Drug Administration (FDA) recently cleared ivWatch Model 400 from ivWatch, LLC, a monitoring device that will improve patient care by quickly detecting IV infiltration and extravasation.
Gary Warren, President and CEO of ivWatch, LLC, said, "It's very rare that one gets an opportunity to be involved in something that can have such a large impact affecting so many people. IVs are probably the most common medical procedure performed and 30 percent of them fail, often as a result of infiltration. It's a huge problem. Others have tried to solve it, but we are the first to develop the technology and bring a practical and cost-effective solution to market."
The ivWatch works through an infrared sensor that is stuck next to the IV site, which is able to non-invasively detect IV fluid leaking outside the vein.
The device can reliably detect 4 cc leakage and works with both forearm and back of the hand IV administration sites. In clinical trials, the device was able to detect leakages down to 1 cc.
ivWatch is automatic and notifies clinical staffs to check the IV as soon as leakage is detected. The device will relieve staffs from frequent checking of IV sites and lead to safer experience for the patients.